Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

FDA Accepts Futibatinib for Priority Review for FGFR2 Rearrangements and Fusions in Cholangiocarcinoma

March 30th 2022, 7:08pm

Article

Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.

AstraZeneca's Camille Hertzka Discusses Interim PROpel Trial Findings in mCRPC

February 25th 2022, 11:30pm

Video

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).

Further Analysis Needed to Incorporate Liquid Biopsy in the Community Setting

February 23rd 2022, 11:50pm

Article

This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.

Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study

February 18th 2022, 12:15pm

Article

A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.

Improvement Needed for Liquid Biopsy to Have Clinical Utility in Lung Cancer

February 15th 2022, 11:00pm

Article

This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.

More Info Needed to Establish Utility of MRD, SFLC Levels as Biomarkers in MM

February 12th 2022, 12:00pm

Article

This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.

ctDNA Detection in RCC Requires More Sensitive Detection Methods

February 8th 2022, 7:00pm

Article

Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.

Liquid Biopsy May Have Prognostic, Theranostic Benefits in PDAC

February 5th 2022, 7:00pm

Article

Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.

Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer

February 2nd 2022, 9:45pm

Article

Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).

Point-of-Care Testing Has Potential to Expand the Reach of NGS for CRC

January 27th 2022, 10:30pm

Article

This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).